FIELD: immunology; medicine.
SUBSTANCE: present invention relates to the field of immunology and medicine, and it is a therapeutic antibody that inhibits binding of IL-11 to an alpha subunit of an IL-11RA receptor and signaling through its receptor and/or binding of an IL-11/IL-11RA complex to a beta subunit of an interleukin-6 receptor, as well as relates to its use for the treatment of patients with oncological diseases in which a high level of expression of IL-11 and/or IL-11RA is observed.
EFFECT: technical result is obtaining a therapeutic antibody specific to interleukin-11, inhibiting signaling through its receptor for the treatment of patients.
2 cl, 7 ex, 23 dwg, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES FOR LABORATORY DIAGNOSTICS OF THE CONCENTRATION OF INTERLEUKIN-11 | 2020 |
|
RU2763178C2 |
| ANTI-IL-22R-ANTIBODIES | 2017 |
|
RU2758721C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| ANTIBODIES TO HUMAN NKG2D AND THEIR APPLICATION | 2008 |
|
RU2563343C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| ANTI-LAG-3 ANTIBODIES AND THEIR COMPOSITIONS | 2017 |
|
RU2755503C2 |
| ANTIBODY THAT BINDS TO VEGF AND IL-1BETA, AND METHODS OF USE THEREOF | 2019 |
|
RU2816476C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
